FAQ on Telomir Pharmaceuticals' Participation in BIO 2025 and IND Preparation for Telomir-1

What is Telomir Pharmaceuticals announcing?

Telomir Pharmaceuticals announced its participation in the BIO International Convention 2025 to explore licensing, M&A, and strategic collaborations, alongside preparing to submit an IND application for its lead candidate, Telomir-1.

What is Telomir-1 and its purpose?

Telomir-1 is a novel small molecule designed to elongate telomeres and reverse core aging mechanisms, with potential therapeutic applications across various diseases including Progeria, Werner’s syndrome, and Type 2 diabetes.

When and where is the BIO International Convention 2025 taking place?

The BIO International Convention 2025 is scheduled for June 16–19 in Boston.

What are the expected milestones for Telomir-1?

Telomir Pharmaceuticals expects to submit an IND application by year-end and initiate first-in-human dosing in the first half of 2026.

What diseases could Telomir-1 potentially treat?

Telomir-1 has shown preclinical potential in treating rare diseases like Progeria and Werner’s syndrome, as well as conditions such as Type 2 diabetes, aggressive prostate cancer, and macular degeneration.

How does Telomir-1 work?

Telomir-1 is designed to lengthen the DNA’s protective telomere caps, which shorten with age, thereby aiming to reverse aging mechanisms and enhance quality of life.

Where can I find more information about Telomir Pharmaceuticals?

More information about Telomir Pharmaceuticals can be found on their website at www.Telodx.com and in their newsroom at https://ibn.fm/TELO.

What is the significance of Telomir Pharmaceuticals’ participation in BIO 2025?

Participation in BIO 2025 allows Telomir Pharmaceuticals to engage in BIO One-on-One Partnering, exploring opportunities for licensing, mergers and acquisitions, and strategic collaborations to advance Telomir-1.

What is the broader aim of Telomir Pharmaceuticals?

The company aims to lead development in longevity science for both humans and animals, with the goal of promoting longevity and enhancing overall quality of life through Telomir-1.